



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, DC 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/261,537	06/17/94	STEINMAN	20164000053

MORGAN & FINNEGAN  
345 PARK AVENUE  
NEW YORK NY 10154

18M2/0415

EXAMINER  
LANE FORD JR., L

#15

ART UNIT  
1808

PAPER NUMBER

DATE MAILED: 04/15/97

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks.

# Office Action Summary

Application No.

08/261,537

Applicant(s)

Steinman et al

Examiner

L. Blaine Lankford

Group Art Unit

1808



☒ Responsive to communication(s) filed on Mar 5, 1997

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claims

☒ Claim(s) 1-23 is/are pending in the application.

Of the above, claim(s) 14-21 is/are withdrawn from consideration.

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☒ Claim(s) 1-13, 22, and 23 is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been  
☐ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1808

### **DETAILED ACTION**

Acknowledgement is made of the receipt and entry of the amendment filed 3-5-97.

The rejection under 35 USC 102 have been overcome by applicant's arguments however the obviousness rejections are maintained for the reasons on record.

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103.

Art Unit: 1808

Claims 1-12 are rejected under 35 U.S.C. § 103 as being unpatentable over Markowicz et al. in view of Jakoby et al.

Markowicz et al., relied upon for the reasons discussed in the previous office action, teach utilization of 100 U/ml of GM-CSF and IL-4. Markowicz et al. differs from the claimed invention by not specifically indicating the exact concentration level of IL-4 utilized and also by teaching the utilization of a slightly less concentration level of GM-CSF from that which is specifically claimed. However, it is well known in the art to adjust the concentration level of culture medium additives in order to optimize the experimental conditions for the particular cell type being cultured. Jakoby et al., on pages 75-77, teach that it is well known in the art of cell culture to "tailor media" in order to optimize the experimental conditions. Each culture system requires examination of the particular conditions that are best for the type of cell being studied by the investigator. Furthermore, each component of the system, identified as result-effective variables, has its well recognized advantages for the purpose of optimizing the experimental conditions. This type of optimizing experimental conditions is well within the purview of the skilled artisan and is deemed a matter of routine experimentation.

Accordingly, the claimed invention would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made, especially in the absence of sufficient, clear and convincing evidence to the contrary.

Applicant's arguments have been fully considered but they are not deemed to be persuasive. In response to Applicant's piecemeal analysis of the references, it has been held that

Art Unit: 1808

one cannot show non-obviousness by attacking references individually where, as here, the rejections are based on combinations of references. *In re Keller*, 208 USPQ 871 (CCPA 1981).

Jakoby is provided as a showing that optimization of cell culture components was old and well known in the art and thus obvious to one of ordinary skill in the art.

Claims 7 and 13 are rejected under 35 U.S.C. § 103 as being unpatentable over Markowicz et al. as applied to claims 1-5 and 10 above, and further in view of Koch et al.

Markowicz et al. differs from claim 8 by not specifically teaching that the culture medium may further comprise TNF-alpha.

Koch et al teach that new insight into the biology of dendritic cells (DC) came from studies of murine epidermal Langerhans cells (LC) *in vitro*. Koch et al. indicate that such studies have suggested that LC in the skin and DC in other non-lymphoid tissues represent precursors or immature elements of the dendritic cell system. Koch et al. teaches that the addition of TNF-alpha to murine epidermal Langerhans cells in culture allows such cells to maintain their viability. Therefore, in view of the teachings of Koch et al., one of ordinary skill in the art would have a reasonable expectation of success in maintaining viability of dendritic cells when TNF-alpha is added to a dendritic cell culture. Accordingly, one of ordinary skill in the art would have had a reasonable expectation of success in adding TNF-alpha to the dendritic cell culture of Markowicz et al. As decided in *In re O'Farrel*, 7 USPQ 2d 1673 (Fed. Cir. 1988), obviousness does not require absolute predictability of success. Indeed, for many inventions that seem quite

Art Unit: 1808

obvious, there is no absolute predictability of success until the invention is reduced to practice. There is always at least a possibility of unexpected results, that would then provide an objective basis for showing that the invention, although apparently obvious, was in law nonobvious. In re Merck & Co., 800 F.2d at 1098, 231 USPQ at 380; Lindemann Maschinenfabrik GMBH v. American Hoist & Derrick Co., 730 F.2d 1452, 1461, 221 USPQ 481, 488 (Fed. Cir. 1984); In re Papesch, 315 F.2d 381, 386-387, 137 USPQ 43, 47-48 (CCPA 1963). For obviousness under 35 U.S.C. 103, all that is required is a reasonable expectation of success. In re Longi, 759 F.2d 887, 897, 225 USPQ 645, 651-652 (Fed. Cir. 1985); In re Clinton, 527 F.2d 1226, 1228, 188 USPQ 365, 367 (CCPA 1976).

In conclusion, the claimed invention would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made, especially in the absence of sufficient, clear and convincing evidence to the contrary.

Applicant's arguments have been fully considered but they are not deemed to be persuasive. In response to Applicant's piecemeal analysis of the references, it has been held that one cannot show non-obviousness by attacking references individually where, as here, the rejections are based on combinations of references. *In re Keller*, 208 USPQ 871 (CCPA 1981).

Koch is provided to demonstrate the obvious use of TNF- $\alpha$  in cell culture of this variety.

Art Unit: 1808

Claims 8-9 and 23 are rejected under 35 U.S.C. § 103 as being unpatentable over Markowicz et al. as applied to claims 1-5 and 10 above, and further in view of Voorhis et al or Ruley et al.

Markowicz et al. differs from claims 8-9 and 23 by adding 10% heat-inactivated human serum as opposed to 1-15% fetal calf serum or 5% cord blood serum. However, Voorhis et al teach that human dendritic cells may be cultured in 5-10% fetal calf serum. Furthermore, it is well known in the animal cell culture field to utilize cord blood serum in animal cell cultures. See, e.g., Ruley et al., U.S. Patent No. 5,364,783, column 22, lines 21-27. Therefore it is deemed merely a matter of judicious selection on the part of the skilled artisan to utilize fetal calf serum or cord blood serum as opposed to human serum. Additionally, it is well known in the art to utilize anywhere from 1-20% of serum in animal cell cultures. Utilization of a particular concentration within that range is deemed merely a matter of routine optimization which is well within the purview of the skilled artisan.

Accordingly, the claimed invention would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made, especially in the absence of sufficient, clear and convincing evidence to the contrary.

Applicant's arguments have been fully considered but they are not deemed to be persuasive. In response to Applicant's piecemeal analysis of the references, it has been held that one cannot show non-obviousness by attacking references individually where, as here, the rejections are based on combinations of references. *In re Keller*, 208 USPQ 871 (CCPA 1981).

Art Unit: 1808

Voorhis et al and Ruley et al have been cited to demonstrate that the art teaches that serum is useful in nerve cell cultures.

The arguments regarding the rejections based on the Hueffler reference are convincing and those rejections are hereby withdrawn.

No claim is allowed.

1. Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made especially in the absence of evidence to the contrary.
2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to L. Blaine Lankford whose telephone number is (703) 308-2455.

LBL

April 14, 1997

  
BLAINE LANKFORD  
PATENT EXAMINER  
GROUP 1800